| Literature DB >> 35059176 |
Qian Shang1, Haifang Tang1, Yongping Liu2, MingMing Yin2, Lebin Su1, Shimin Xie1, Lixin Liu1, Wen Yang1, Yi Chen2, Jianyu Dong3, Yongbo Zhou1, Shuang-Feng Yin1.
Abstract
Selective condensation/bicycloaromatization of two different arylalkynes is firstly developed under ligand-free copper(i)-catalysis, which allows the direct synthesis of C-N axial biaryl compounds in high yields with excellent selectivity and functional group tolerance. Due to the critical effects of Cu(i) catalyst and HFIP, many easily occurring undesired reactions are suppressed, and the coupled five-six aromatic rings are constructed via the selective formation of two C(sp2)-N(sp2) bonds and four C(sp2)-C(sp2) bonds. The achievement of moderate enantioselectivity verifies its potential for the simplest asymmetric synthesis of atropoisomeric biaryls. Western blotting demonstrated that the newly developed compounds are promising targets in biology and pharmaceuticals. This unique reaction can construct structurally diverse C-N axial biaryl compounds that have never been reported by other methods, and might be extended to various applications in materials, chemistry, biology, and pharmaceuticals. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35059176 PMCID: PMC8694356 DOI: 10.1039/d1sc03865f
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Scheme 1Strategies to construct biaryl compounds.
Fig. 1Biologically active 1,1′-naphthylindole derivatives.
Scheme 2Condensation/bicycloaromatization of o-amino and o-carbonyl arylalkynes.
Optimization of reaction conditionsa
|
| |||||
|---|---|---|---|---|---|
| Entry | [Cu] | Solvent |
| Additive | Yield |
| 1 | CuCl | HFIP | 100 | — | 64 |
| 2 | CuBr | HFIP | 100 | — | 70 |
| 3 | CuOAc | HFIP | 100 | — | 79 |
|
|
|
|
|
|
|
| 5 | CuCl2 | HFIP | 100 | — | 8 |
| 6 | Cu(OAc)2 | HFIP | 100 | — | 10 |
| 7 | Pd(OAc)2 | HFIP | 100 | — | 7 |
| 8 | PdCl2 | HFIP | 100 | — | 6 |
| 9 | CuI | TFE | 100 | — | 60 |
| 10 | CuI | PFTB | 100 | — | 66 |
| 11 | CuI | EtOH | 100 | — | 4 |
| 12 | CuI | Propanol | 100 | — | Trace |
| 13 | CuI | IPA | 100 | — | 10 |
| 14 | CuI | TBA | 100 | — | 8 |
| 15 | CuI | Toluene | 100 | — | Trace |
| 16 | CuI | DMF | 100 | — | Trace |
| 17 | CuI | THF | 100 | — | 10 |
| 18 | CuI | DCM | 100 | — | 19 |
| 19 | CuI | HFIP | 60 | — | 53 |
| 20 | CuI | HFIP | 120 | — | 82 |
| 21 | CuI | HFIP | 100 | Na2CO3 | 84 |
| 22 | CuI | HFIP | 100 | K3PO4 | 87 |
| 23 | CuI | HFIP | 100 |
| 88 |
| 24 | CuI | HFIP | 100 | Cs2CO3 | 91 |
| 25 | CuI | HFIP | 100 | TsOH | Trace |
| 26 | CuI | HFIP | 100 | HOAc | Trace |
|
|
|
|
|
|
|
| 28 | CuI | HFIP | 100 | Cs2CO3 | 95 |
| 29 | CuI | HFIP | 100 | Cs2CO3 | 94 |
Reaction conditions: unless otherwise stated, all reactions were performed with 1a (0.05 mmol), 1b (1.0 equiv., 0.05 mmol), catalyst (10 mol%), and additive (2.0 equiv., 0.1 mmol) in the solvent (0.5 mL) at 100 °C for 24 h under N2 atmosphere.
GC yield based on 1a using dodecane as an internal standard.
1a (0.05 mmol), 1b (0.06 mmol).
HFIP (1.0 mL).
HFIP (1.5 mL). TFE (2,2,2-trifluoroethanol), PFTB (perfluoro-tert-butyl alcohol), IPA (iso-propyl alcohol), TBA (tert-butyl alcohol).
Scheme 3Substrate scope.
Scheme 4Scope of heteroaryl alkynes. aReaction conditions: a (0.05 mmol), b (1.2 equiv., 0.06 mmol), CuI (10 mol%), Cs2CO3 (2.0 equiv.), HFIP (1.0 mL), 100 °C, 24 h, N2. Isolated yields are provided.
Scheme 5Control experiments.
Scheme 6Possible reaction mechanism.
Scheme 7Substrate scope of axially chiral compounds. Reaction conditions: (1) a (0.2 mmol), 4b (1.2 equiv.), CuI (5 mol%), Cs2CO3 (2.0 equiv.) HFIP, 80 °C, 50 min; (2) PdCl2 (5 mol%), L (6 mol%) HFIP, 80 °C, 15 h.
Fig. 2BV2 cells were pretreated with 10 μM A1 for 2 h and then treated with LPS (100 ng mL−1) for 6 h. (a) The levels of P65 and the corresponding phosphorylated form were measured by western blotting (n = 3 per group). Compared with the control group, **P < 0.01, vs. LPS group, *P < 0.05. (b) BV2 cells were pretreated with different concentrations (5–20 μM) of A1 for 2 h and were then treated with 100 ng mL−1 LPS for 6 h. The levels of IL-6 were detected by western blotting (A1 = 15c).